| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Citi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2009-01-22 16:06:21 |
| Versijas komentārs | |
| Teksts |
JSC “Grindeks” informs that the Business plan of the Company anticipates 185 million Lats turnover for 2013. Published information on BNS (22.01.2009.) – increase of the turnover reaching 300 million Lats in 7-8 year period will be possible only if current growth dynamics will sustain in existing and new markets. Also we inform, that JSC “Grindeks”continues the registration process of original brand product Mildronate® in China, but exact terms of registration completion is prematurely to announce. About “Grindeks” JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of “Grindeks”’s products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. “Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”. Contacts: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phones: +371 67083370, + 371 29256012 e-mail: laila.klavina@grindeks.lv |
| Pielikumi |
|